Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: RWReeves who wrote (1110)	5/18/2000 5:11:00 PM
From: Mike McFarland	Respond to of 52153

Yeah I'd thought that phase I was generally a safety trial, but naturally with these cancer patients that isn't often the case. Of course I am only seeing two cancers times six patients each and only one table is given, with one death-- As you say, the statistics are not there. In the other tgen paper no data is given with the abstract--and that is the one that is more interesting with 24pts and combination therapy (#1808, 1809 if you're slogging like Peter). Well, I knew I was in for a long term commitment and several years of trials with that one and mostly I wanted to be on the AAV CF gene therapy. I should probably have been snooping around for companies in late stage trials, but I'm on the graveyard shift anyway this week and wouldn't be trying to do any trades anyway (not that you should try and pull trades based on abstracts!).